myeloid malignancies Flashcards

1
Q

myeloid malignancies

A

myeloid origin

myeloid progenitor cells, red cells, platelets, granuolcytes, monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

AML lineage

A

myeloiod progenitor cell

proliferation without differentiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

AML general points

A
  • leukemic cells don’t differentiate
  • bone marrow failure
  • rapidly fatal if untreated
  • potentially curable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CML general points

A
  • leukaemic cells retain ability to differentiate
  • proliferation wout bone marrow failure
  • survival for few years
  • long term survival/possible cure w modern therapies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

subgroups of acute leukemia

A

acute myeloblastic leukaemia

acute lymphoblastic leukaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AML: why does bone marrow failure happen

A

acute leukemic cells replace bone marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AML classic triad

A

anaemia: tired, SOB, heart failure
thrombocytopenia: purpura, mucosal bleeding
neutropenia: infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AML bone marrow aspirate findings

A

AML = >20% bone marrow is blasts

<20% then myelodysplastic syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

AML Ix

A
blood count + blood film 
bone marrow aspirate
cytogenic from blasts
immunophenotyping blast: determine lymphoid or myeloid origin 
CSF if symptomatic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

RX AML

A

supportive care: specialist unit, early recognition neutropenic sepsis
anti-leukaemic chemotherapy
SCT
all-trans retinoic acid and arsenic trioxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

AML antileukemic chemotherpay

A

daunorubicin + cytosine arabinoside
high dose cytoisne arabinoside

to induce and consolidate remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AML remission

A

normal blood count and <5% blasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

new developments in AML

A

targeted antibodies: gentuzumab oozaigimicin
targeted small molecules: midostaurin - tyrosine kinsase inhibitor
new chemo delivery systems: CPX-351

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

CML features

A
anaemia of chronic disease
splenomegaly 
gout 
weight loss
hyperleukostasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CML hyperleukostasis

A

high WCC
fundal heamorrhage, venous congestion
alt consciousness
resp failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CML lab features

A

high WCC
high platelets
anaemia
blood film shows all stages white cell differentiation + inc basophila
bone marrow hypercellular
bone marrow + blood cells contain philadelphia chromosome t(9;22): overproduction of abnormal fusion gene fusion

17
Q

CML treatment

A

tyrosine kinase inhibitors first line; direct inhibition BCR-ABL (philadelphia chromosome)

transplant in TKI failure

18
Q

myeloprolipherative neoplasm examples

A

polycythemia vera
essential thrombocythemia
idiopathic myelofibrosis

19
Q

myeloprolipherative neoplasm mutation

A

JAK2 V617F mutation

JAK2 activation without erythropoetin binding
independant stimulation red cell production

20
Q

polycythemia vera clinical features

A
headaches
itch 
vascular occlusion 
TIA, stroke
splenomegaly 
plethora (red facies)
21
Q

polycythemia vera lab features

A

raised Hb and raised haematocrit
tendency to raised WCC + platelets
raised uric acid (risk gout)
increase in red cell mass

22
Q

polycythemia vera Rx

A
  • venesection to lower haematocrit (blood letting)
  • aspirin: reduce risk thrombosis
  • hydroxycarbamide/alpha interferon
  • ruxolitinib (JAK2 inhibitor) in hydroxycarbamide failure
23
Q

polycythemia vera natural history

A
  • stoke and other thromboses if poorly controlled
  • bone marrow failure from development 2ry myelofibrosis
  • transformation to AML
24
Q

essential thrombocythaemia

A

myeloproliferative disease with predominant feature of raised platelet count

25
Q

essential thrombocythaemia symptoms

A
thromboses
digital ischaemia
gout 
headache
mild splenomegaly
26
Q

essential thrombocythaemia Mx

A

aspirin

hydroxycarbamide

27
Q

essential thrombocythaemia progression

A

can progress to myelofibrosis or AML